CAPR241115C22500
- 2.03
- +0.63+45.00%
Capricor Therapeutics Newsroom
Express News | Capricor Therapeutics Files Prospectus Relates to Resale by Selling Stockholder of up to 2.8 Mln Shares of Common Stock -SEC Filing
Capricor Therapeutics Analyst Ratings
Retail Investors Account for 45% of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Ownership, While Institutions Account for 14%
Piper Sandler Initiates Capricor Therapeutics(CAPR.US) With Buy Rating, Announces Target Price $35
Buy Rating for Capricor Therapeutics: Promising Deramiocel Development and Strategic Partnerships
Express News | Capricor Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $35
CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday
Capricor Therapeutics Shares Slip Premarket on Stock Offering
Express News | Capricor Therapeutics Inc - Prices Offering of 4,412,000 Shares at $17.00 per Share
Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
Press Release: Capricor Therapeutics Announces Proposed Public Offering of Common Stock
Capricor Therapeutics May Offer And Sell Up To $150M In Common Stock, Preferred Stock, Debt Securities, Warrants, And Units In One Or More Offerings
10 Health Care Stocks With Whale Alerts In Today's Session
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Capricor Therapeutics (CAPR) Receives a Buy From Oppenheimer
$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,800 Today
Fastenal Posts Upbeat Earnings, Joins Wells Fargo, JPMorgan And Other Big Stocks Moving Higher On Friday
Capricor Reports Positive Data in Duchenne Muscular Dystrophy Study; Shares Rise
Capricor Therapeutics Announces Positive Long-Term Data From HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress